Genaissance Pharmaceuticals, Inc. Invites You to Participate in its Fourth Quarter 2004 Conference Call

Genaissance Pharmaceuticals, Inc. Invites You to Participate in
its Fourth Quarter 2004 Conference Call 


NEW HAVEN, Conn., Feb. 3  /PRNewswire-FirstCall/ -- Genaissance
Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that the Company would
conduct a conference call on Thursday, February 10, 2005, at 11:30 a.m. Eastern
time (ET), in conjunction with the release of its financial results for the
fourth quarter ended December 31, 2004.

"The past year's activities have put us in a strong position to achieve major
objectives in our partnering and portfolio development programs," said Kevin
Rakin, President and Chief Executive Officer of Genaissance.  "The revenue
growth we expect in 2005 should narrow our losses and potentially bring us to
positive operating cash flow by the fourth quarter, based on current levels of
program funding."

To participate in this conference call, dial 913-981-5510, confirmation code
2415972, shortly before 11:30 a.m. ET.  A replay of the call will be available
from 2:30 p.m. ET through midnight Wednesday, February 16, 2005. The replay
number is 719-457-0820, confirmation code 2415972.

Genaissance Pharmaceuticals, Inc. is developing innovative products based on
its proprietary pharmacogenomic technology and has a revenue-generating
business in DNA and pharmacogenomic products and services.  Genaissance also
markets its proprietary FAMILION(TM) Test, designed to detect mutations
responsible for causing Familial Long QT and Brugada Syndromes, two causes of
sudden cardiac death.  The Company's product development strategy is focused on
drug candidates with promising clinical profiles and finding genetic markers to
identify a responsive patient population.  This strategy enables Genaissance to
leverage existing clinical data and, thus, reduce the costs and risks
associated with traditional drug development and increase the probability of
clinical success and commercialization.  The Company's lead therapeutic
product, vilazodone for depression, is in Phase II of development. For more
information on Genaissance, visit our website at: http://www.genaissance.com/. 

DATASOURCE: Genaissance Pharmaceuticals, Inc.



CONTACT:  Rhonda Chiger, of Rx Communications Group, [phone],





Web site:  http://www.genaissance.com/ 

Copyright